ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data

After teasing positive top-line results last November, a deeper dive into Merck & Co. and Bayer’s heart failure drug vericiguat helped kick off this year’s scientific meeting of the American College of Cardiology, presented virtually as a late-breaking trial.